Viewing Study NCT02042950


Ignite Creation Date: 2025-12-24 @ 4:58 PM
Ignite Modification Date: 2026-02-17 @ 10:26 PM
Study NCT ID: NCT02042950
Status: TERMINATED
Last Update Posted: 2019-05-01
First Post: 2014-01-21
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Sponsor: M.D. Anderson Cancer Center
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Lymphoma View
None Mantle Cell Lymphoma View
None MCL View
None Relapsed View
None Refractory View
None Carfilzomib View